Lilly’s Mounjaro Enters China’s State Insurance System
Eli Lilly achieved a major market access milestone after Mounjaro was officially added to China’s national medical insurance list for diabetes treatment, dramatically improving affordability and penetration prospects across the country. The inclusion allows millions of Chinese patients with type 2 diabetes to access tirzepatide at reimbursed prices for the first time, accelerating domestic adoption. The decision also strengthens Lilly’s competitive position against Novo Nordisk in the world’s largest diabetes market. Industry analysts view the move as a turning point for high-end metabolic biologics in China’s reimbursement system, signaling a broader willingness to cover premium innovation.
You May Interested In
2026-09-01
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Profits Are Rising, but So Are the Risks—China’s Coatings Industry Is Living Through Its Most Awkward Year
-
Antidumping Pressure Hits the Chemical Chain as Chinese Exports Face Higher Barriers in Europe
-
IEA Warns Oil Inventories Are Draining Fast as Chemicals Enter Risk Pricing
-
One Million Tonnes of U.S. Ethane Arrive as China Sets a New Import Record
-
EU Puts Chemicals on Its China De-Risking Watchlist
-
Sulfur Price Hits 7,633 CNY/Ton, Up Nearly Sixfold in a Year and a Half; Domestic Refining Giants Halt New Orders Due to Tight Supply
-
A $25 Billion Bill Hits Global Companies as Chemical Costs Are Repriced
-
Invista Reshuffles Global Nylon 66 Map: Shutting US and UK Plants, Betting Big on China—What Exactly Are They Aiming For?
-
China’s Chemical “Spring Surge”: 68.8% of Products Rising—Real Recovery or Just a Pre-Festival Mirage?
-
French Cosmetics Exports Poised for First Drop in Over Two Decades in 2025
Recommend Reading
-
![EFSA Unable to Confirm Safety of Fusarium flavolapis Fungal Protein as a Novel Food]()
EFSA Unable to Confirm Safety of Fusarium flavolapis Fungal Protein as a Novel Food
-
![EFSA Confirms Safety of β-Amylase Produced from Barley for Food Manufacturing Use]()
EFSA Confirms Safety of β-Amylase Produced from Barley for Food Manufacturing Use
-
![EU Officially Approves Rapeseed Oil as a Low-Risk Active Substance Until 2040]()
EU Officially Approves Rapeseed Oil as a Low-Risk Active Substance Until 2040
-
![India Accuses Balaji Amines of Manufacturing Pharma-Grade Propylene Glycol Without Drug Manufacturing Licence]()
India Accuses Balaji Amines of Manufacturing Pharma-Grade Propylene Glycol Without Drug Manufacturing Licence
-
![EFSA Evaluates Extended Use of Pasteurised Akkermansia muciniphila as a Novel Food]()
EFSA Evaluates Extended Use of Pasteurised Akkermansia muciniphila as a Novel Food
-
![Business Society’s Market Outlook for Epichlorohydrin on August 17, 2026: Volatile Consolidation]()
Business Society’s Market Outlook for Epichlorohydrin on August 17, 2026: Volatile Consolidation
-
![Sulfate Ammonium Market Continues to Rise (10.9-10.16)]()
Sulfate Ammonium Market Continues to Rise (10.9-10.16)
-
![Business Society’s August 17, 2026 Butadiene Market Outlook: Volatile]()
Business Society’s August 17, 2026 Butadiene Market Outlook: Volatile
-
![Business Society’s Market Outlook for Propylene Oxide on August 17, 2026: Volatile Trend]()
Business Society’s Market Outlook for Propylene Oxide on August 17, 2026: Volatile Trend
-
![Business Society’s Market Outlook for Acrylic Acid on August 18, 2026: Weak Rebound]()
Business Society’s Market Outlook for Acrylic Acid on August 18, 2026: Weak Rebound
